Store rating
-
Store ratings
-
AVALW mentions
0
Price
Free
Platforms
3
Listed
Nov 19, 2026
Screenshots
About J3M-MC-JZQB CN
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.
AVALW Coverage
Not yet mentioned in AVALW articles.